MktsMarkets

Viridian Therapeutics, Inc.
NASDAQ: VRDNKey statistics
VRDN News
Stories mentioning VRDN from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | ||||||||
| Cost of Goods Sold | ||||||||
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | ||||||||
| Research & Development | ||||||||
| Sales General & Admin | 38,679 | 17,103 | ||||||
| Total Operating Expenses | 116,310 | 122,881 | 110,583 | 106,842 | 93,938 | 87,543 | 83,566 | 72,259 |
| Operating Income (Loss) | (116,169) | (122,749) | (40,013) | (106,767) | (93,866) | (87,471) | (83,480) | (72,187) |
| Interest Income | 7,872 | 5,521 | 7,540 | 7,515 | ||||
| Interest Expense | ||||||||
| Other Expense | ||||||||
| Pretax Income | ||||||||
| Tax Provision | ||||||||
| Net Income (Loss) | (104,901) | (120,355) | (34,599) | (100,735) | (86,912) | (79,725) | (76,689) | (64,993) |
| Earnings Per Share (Basic) | (1.15) | (1.02) | ||||||
| Earnings Per Share (Diluted) | (1.15) | (1.02) | ||||||
| Weighted Average Shares Outstanding (Basic) | 66,420 | 63,855 | ||||||
| Weighted Average Shares Outstanding (Diluted) | 81,344 | 66,420 | 63,855 | |||||
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About VRDN
Viridian Therapeutics, Inc. (NASDAQ: VRDN) is a stock listed on the Nasdaq Stock Market under the ticker symbol VRDN. It last traded at $30.87 (Nov 13, 2026, 4:00 PM ET), up 1.3% on the day. That gives Viridian Therapeutics a market capitalisation of $3.4B.
Over the past 52 weeks VRDN has traded between $13.18 and $34.29.
For the quarter ended Mar 31, 2026 it reported a net loss of $104.9M.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Mar 31, 2026 | — | -$104.9M |
| Dec 31, 2025 | — | -$120.4M |
| Sep 30, 2025 | — | -$34.6M |
| Jun 30, 2025 | — | -$100.7M |
From Viridian Therapeutics’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…